Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948756 | 0.88 | ALDH1A1 (0.47) | HCAR2ALDH1A1LMNAESR1TSHR | |
| SCHEMBL2945350 | 0.87 | HCAR2 (0.40) | HCAR2ALDH1A1LMNAESR1CHRM1 | |
| SCHEMBL2949588 | 0.86 | CA12 (0.47) | HCAR2ALDH1A1LMNATSHR | |
| SCHEMBL2946420 | 0.85 | NAAA (0.48) | HCAR2ALDH1A1LMNATSHR | |
| SCHEMBL2941644 | 0.83 | — | — | |
| SCHEMBL2944738 | 0.82 | HCAR2 (0.43) | HCAR2ALDH1A1LMNAESR1CHRM1 | |
| SCHEMBL2941830 | 0.81 | ALDH1A1 (0.42) | HCAR2ALDH1A1LMNAESR1CHRM1 | |
| SCHEMBL3411726 | 0.80 | CA12 (0.44) | HCAR2ALDH1A1TSHR | |
| SCHEMBL2945262 | 0.79 | ACHE (0.35) | HCAR2ALDH1A1LMNAESR1CHRM1 | |
| SCHEMBL2942620 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727677-B2 | Nonaqueous electrolyte solution and lithium secondary battery using same | UBE INDUSTRIES, LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| EP-1758198-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | UBE INDUSTRIES (JP) | 2009-07-08 | — | — | EP | disclosed |
| US-20080038644-A1 | Nonaques Electrolyte Solution And Lithium Secondary Battery Using Same | UBE INDUSTRIES, LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1758198-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | Ube Industries, Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20070043002-A1 | Aldolase-inhibiting aromatic compounds | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043002-A1 | Aldolase-inhibiting aromatic compounds | ALDOA, DERA, AKR1B1 | HCAR2 974/4885ALDH1A1 17/4885LMNA 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.